Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B ...

Pfizer global commercial access partnerships director. Addressing challenges in prevention, personnel, facilities, and treatment can have a sweeping effect on the health of a population.

we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat Yalcinkaya, Pfizer Gulf ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for their global clinical trials that include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials ... testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...